Latest news
Argent Biopharma's CannEpil to Target $3bn Veterinary Pain Market, Weeks After Debt-Relief Deal - Business of CannabisBusiness of Cannabis · Thu, 06 Aug 2026 11:23:02 GMTArgent’s CannEpil expands into veterinary market - The AustralianThe Australian · Thu, 06 Aug 2026 05:10:00 GMTArgent BioPharma (ASX:RGT): Why Does Cannepil Development Pathway Matter? - Kalkine MediaKalkine Media · Thu, 06 Aug 2026 03:18:00 GMTArgent BioPharma Advances CannEpil into U.S. Veterinary Market with New Development Program - TipRanksTipRanks · Wed, 05 Aug 2026 23:34:17 GMTSplash Beverage launches cannabinoid veterinary oncology collaboration - TipRanksTipRanks · Wed, 05 Aug 2026 23:05:43 GMTSplash Beverage Group Partners with Veteran Cannabinoid Drug-Development Team to Advance CannEpil® Through FDA Veterinary Pathway - marketscreener.commarketscreener.com · Wed, 05 Aug 2026 12:31:24 GMTSplash's CannEpil Program Is Expected to Target Cancer and Pain in Dogs - Stock TitanStock Titan · Wed, 05 Aug 2026 12:30:00 GMTKura Oncology to Report Second Quarter Financial Results - The Manila TimesThe Manila Times · Wed, 05 Aug 2026 11:38:20 GMT